ALCJ Fundamental Analysis - CROSSJECT

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ALCJ. ALCJ was compared to 62 industry peers in the Health Care Equipment & Supplies industry. ALCJ may be in some trouble as it scores bad on both profitability and health. ALCJ has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALCJ has reported negative net income.

In the past year ALCJ has reported a negative cash flow from operations.

In the past 5 years ALCJ always reported negative net income.

In the past 5 years ALCJ always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -36.32%, ALCJ is not doing good in the industry: 80.65% of the companies in the same industry are doing better.

ALCJ has a worse Return On Equity (-308.32%) than 87.10% of its industry peers.

		Industry Rank	Sector Rank
ROA	-36.32%
ROE	-308.32%
ROIC	N/A

ROA(3y)-34.79%

ROA(5y)-33.59%

ROE(3y)-356.8%

ROE(5y)-363.27%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALCJ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALCJ has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALCJ has more shares outstanding

The debt/assets ratio for ALCJ has remained at the same level compared to a year ago.

2.2 Solvency

ALCJ has an Altman-Z score of 0.60. This is a bad value and indicates that ALCJ is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.60, ALCJ is doing worse than 69.35% of the companies in the same industry.

A Debt/Equity ratio of 0.71 indicates that ALCJ is somewhat dependend on debt financing.

ALCJ has a worse Debt to Equity ratio (0.71) than 75.81% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.71
Debt/FCF	N/A
Altman-Z	0.6

ROIC/WACCN/A

WACC7.52%

2.3 Liquidity

ALCJ has a Current Ratio of 0.95. This is a bad value and indicates that ALCJ is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.95, ALCJ is doing worse than 83.87% of the companies in the same industry.

A Quick Ratio of 0.76 indicates that ALCJ may have some problems paying its short term obligations.

ALCJ has a worse Quick ratio (0.76) than 74.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.95
Quick Ratio	0.76

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.12% over the past year.

Looking at the last year, ALCJ shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)13.12%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%36.07%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ALCJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 56.77% yearly.

Based on estimates for the next years, ALCJ will show a very strong growth in Revenue. The Revenue will grow by 98.55% on average per year.

EPS Next Y135.12%

EPS Next 2Y83.48%

EPS Next 3Y56.77%

EPS Next 5YN/A

Revenue Next Year428.6%

Revenue Next 2Y140.35%

Revenue Next 3Y98.55%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALCJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

ALCJ is valuated cheaply with a Price/Forward Earnings ratio of 6.18.

Compared to the rest of the industry, the Price/Forward Earnings ratio of ALCJ indicates a rather cheap valuation: ALCJ is cheaper than 95.16% of the companies listed in the same industry.

ALCJ is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.18

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALCJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

ALCJ's earnings are expected to grow with 56.77% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y83.48%

EPS Next 3Y56.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALCJ!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

CROSSJECT

EPA:ALCJ (12/31/2025, 7:00:00 PM)

2.19

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)09-24 2025-09-24

Earnings (Next)03-25 2026-03-25/amc

Inst Owners0.37%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap113.75M

Revenue(TTM)N/A

Net Income(TTM)-11.26M

Analysts84.44

Price Target3.88 (77.17%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)15.15%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-37.41%

EPS NY rev (3m)39.71%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)36.82%

Revenue NY rev (3m)29.25%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.18
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	34.71
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.23

EYN/A

EPS(NY)0.35

Fwd EY16.18%

FCF(TTM)-0.18

FCFYN/A

OCF(TTM)-0.11

OCFYN/A

SpS0

BVpS0.06

TBVpS-0.11

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-36.32%
ROE	-308.32%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-34.79%

ROA(5y)-33.59%

ROE(3y)-356.8%

ROE(5y)-363.27%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.71
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	60.91%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.95
Quick Ratio	0.76
Altman-Z	0.6

F-Score4

WACC7.52%

ROIC/WACCN/A

Cap/Depr(3y)131.18%

Cap/Depr(5y)130.12%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)13.12%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%36.07%

EPS Next Y135.12%

EPS Next 2Y83.48%

EPS Next 3Y56.77%

EPS Next 5YN/A

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year428.6%

Revenue Next 2Y140.35%

Revenue Next 3Y98.55%

Revenue Next 5YN/A

EBIT growth 1Y2.7%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year190.19%

EBIT Next 3Y71.66%

EBIT Next 5YN/A

FCF growth 1Y20.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-66.32%

OCF growth 3YN/A

OCF growth 5YN/A

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA.

Can you provide the valuation status for CROSSJECT?

ChartMill assigns a valuation rating of 4 / 10 to CROSSJECT (ALCJ.PA). This can be considered as Fairly Valued.

What is the profitability of ALCJ stock?

CROSSJECT (ALCJ.PA) has a profitability rating of 0 / 10.

What is the earnings growth outlook for CROSSJECT?

The Earnings per Share (EPS) of CROSSJECT (ALCJ.PA) is expected to grow by 135.12% in the next year.

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

Can you provide the valuation status for CROSSJECT?

What is the profitability of ALCJ stock?

What is the earnings growth outlook for CROSSJECT?